PACTR201411000920150招募中未知
Sildenafil Citrate Therapy for Oligohydramnios
menoufiya university hospital0 个研究点目标入组 184 人开始时间: 2014年10月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 45 Year(s)（—）
- 性别
- Female
入选标准
- •Pregnant women will be included if they are of any age, any parity, carrying a singleton pregnancy, at a gestational age (GA) 30 weeks or more (based on the last menstrual period and confirmed by the results of ultrasound or determined through early pregnancy sonography), they have an AFI ¿ 5, no pregnancy complications such as preeclampsia, gestational hypertension, or diabetes, no prior history of kidney, lung, and heart disease (the use of bolus-fluid therapy is contraindicated in these patients), and intact fetal membranes.
排除标准
- •Mothers treated with prostaglandin synthetase inhibitors, well established labor, evidence of fetal distress (non-reactive non stress test), or fetal complications (intrauterine growth retardation or obvious fetal anomalies) are considered exclusion criteria.
研究者
相似试验
Unknown
不适用
Sildenafil Citrate Therapy for OligohydramniosPregnancy ComplicationNCT02372487Al Hayat National Hospital184
招募中
不适用
Sildenafil citrate for the treatment of asymmetrical intrauterine growth restriction: A randomized controlled trialPregnancy and ChildbirthIntrauterine growth restrictionPACTR201705002278236Ain Shams university80
招募中
2 期
The effects of sildenaphil on oligohydramniosOligohydramnios.OligohydramniosIRCT20091023002624N21Iran University of Medical Sciences190
尚未招募
2 期
Sildenafil citrate to improve maternal and neonatal outcomes in low-resource settings: a randomized feasibility trialNeonatal DiseasesPregnancy and ChildbirthPACTR202303797356166niversity of Alabama at Birmingman500
进行中（未招募）
不适用
Therapy of PAH – Treatment with Sildenafil in Eisenmenger Patients - SildenafilPatients with pre-existing congenital heart disease may develop Eisenmenger physiology (EP), characterized by development of pulmonary arterial hypertension and intracardiac right to left shunt. This Patients suffer from cyanosis and reduced quality of life. While EP has been regarded as not amenable to conventional treatments, new oral drugs as Sildenafil have been used successfully to improve primary arterial hypertension. Thus may be an important treatment option for patients with EP, too.EUCTR2007-002774-64-DEDeutsches Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler80